Inside Sionna’s Bid To Normalize CFTR Function

Send us Fan Mail

Two leaders from Sionna Therapeutics walk through a 15‑year journey from Genzyme science to a public company advancing NBD1‑targeted therapies in cystic fibrosis. We examine why most patients still fall short of normal CFTR, how a predictive assay de‑risks choices, and what it takes to finance, hire, and execute with patients as the North Star.

Visit: sionnatx.com

Visit Labtolives.com

Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/ 

Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/ 

Support the show

________
Reach out to Ivanna Rosendal

Join the conversation on our LinkedIn page

Visit www.labtolives.com 

Hosts

Alexander Booth aka the MedTech Guy

Dimitri Borisevich aka the start-up Guy

Ivanna Rosendal aka the R&D pharma Gal